Table 2: The input parameters for the discounted cash flow model.
| Model parameter | Value |
| Cost of development (US$ million) | US$701 million |
| Cost pre-clinical | US$217 million |
| Phase I | US$84 million |
| Phase II | US$142 million |
| Phase III | US$190 million |
| Phase IV | US$68 million |
| Years of development & approval | 8 years |
| Population | Western markets: 872.5 million |
| Global markets: 1,670 million | |
| Period of reimbursement | 1 year |
| Net patent period after registration | 12 years |
| Uptake | 80% from year 1 |
| Cost of revenue | 40% |
| Hurdle rate | 12% |
| Probability | |
| Phase I to II | 70% (failure - 30%) |
| Phase II to III | 39% (failure - 61%) |
| Phase III to FDA approval* | 69% (failure - 31%) |
*Assumption: Same probability for EMA.